By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Opening Innovativeness: Moving Thoughts and Tasks - 2The most effective method to Pick the Right Material Organization: Your Definitive Aide
- 3'You're no longer my sister' - rows erupt as war divides Iranian families
- 4Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
- 5December’s full moon is the last supermoon of the year. Here’s what to know
- From Exemplary to Current: Famous Rings Available
- UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- Rediscovering Euphoria: Individual Accounts of Conquering Despondency
- Closets for Your Room: Plan and Utility Features
- Fundamental Home Machines for Improved Solace in Summer
- From invasive species tracking to water security – what’s lost with federal funding cuts at US Climate Adaptation Science Centers
- Artemis II live updates: NASA's historic moon mission set to make lunar flyby today
- ‘It’s Israeli policy’: Report reveals abuse of Palestinians in prisons
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
